- Home
- MOBX vs TOVX Comparison
MOBX vs TOVX Comparison
Compare MOBX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOBX | TOVX |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 11.1M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MOBX | TOVX |
|---|---|---|
| Price | $0.57 | $0.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 928.6K | ★ 1.0M |
| Earning Date | 08-18-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,442,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 426.31 | N/A |
| 52 Week Low | $0.13 | $0.14 |
| 52 Week High | $4.25 | $0.49 |
Technical Indicators
Market Signals| Indicator | MOBX | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.62 | 29.84 |
| Support Level | $0.16 | N/A |
| Resistance Level | $0.78 | $0.25 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 28.76 | 29.78 |
Price Performance
Historical ComparisonAbout MOBX Mobix Labs Inc.
Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.